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Abstract: 32 
Pre-eclampsia is a leading cause of maternal death and maternal and perinatal morbidity. 33 
Whilst the clinical manifestations of pre-eclampsia often occur in late pregnancy, the molecular 34 
events leading into the onset of this disease are thought to originate in early pregnancy and 35 
result in insufficient placentation. Although the causative molecular basis of pre-eclampsia 36 
remains poorly understood, maternal inflammation is recognised as a core clinical feature.  37 
While the adverse effects of pre-eclampsia on maternal and fetal health in pregnancy is well-38 
recognised, the long-term impact of pre-eclampsia exposure on the risk of autism spectrum 39 
disorder (ASD) in exposed offspring is a topic of on-going debate. In particular, a recent 40 
systematic review has reported an association between exposure to pre-eclampsia and increased 41 
risk of ASD, however the molecular basis of this association is unknown. Here we review 42 
recent evidence for; 1) maternal inflammation in pre-eclampsia; 2) epidemiological evidence 43 
for alterations in neurodevelopmental outcomes in offspring exposed to pre-eclampsia; 3) long-44 
term changes in the brains of offspring exposed to pre-eclampsia; and 4) how maternal 45 
inflammation may lead to altered neurodevelopmental outcomes in pre-eclampsia exposed 46 
offspring. Finally, we discuss the implications of this for the development of future studies in 47 
this field. 48 
Key words: Pre-eclampsia; autism; behaviour; maternal; inflammation; placenta; cytokine.  49 
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1. Introduction: 73 
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder, characterised by 74 
impairments in social and communication skills, as well as restricted and repetitive patterns of 75 
behaviour (Lord et al., 2018; Thapar et al., 2017; Xiao et al., 2014). ASD is among the most 76 
common neurodevelopmental conditions with a prevalence of approximately 1% globally, and 77 
1.5% in developed countries (Lord et al., 2018; Lyall et al., 2017).  78 
While there is a general consensus that genetics play the major role in the aetiology of 79 
ASD (Sandin et al., 2014), the environmental contribution is estimated to be between 17-50%. 80 
(Sandin et al., 2017; Sandin et al., 2014). Therefore, it is important to investigate factors 81 
potentially contributing to the likelihood of development of ASD.  Several environmental risk 82 
factors, including prenatal and perinatal factors have been examined in an attempt to explain 83 
the aetiology of ASD (Lord et al., 2018). In particular, a recent systematic review examining 84 
the association between hypertensive disorders of pregnancy (HDP) and neurodevelopmental 85 
disorders reported an association between pre-eclampsia and ASD in exposed offspring (Maher 86 
et al., 2018). However, while the molecular basis of this association is not known, it may 87 
involve maternal inflammation given its link to ASD (Brown et al., 2014), and given that 88 
maternal inflammation is a core feature of pre-eclampsia (Lau et al., 2013) (Figure 1). 89 
Therefore, the objectives of this paper are to review and provide a perspective on the:  90 
1. Evidence for maternal inflammation in pre-eclampsia;  91 
2. Epidemiological evidence for alterations in neurodevelopmental outcomes in offspring 92 
exposed to pre-eclampsia;  93 
3. Evidence for long-term changes in the brains of offspring exposed to pre-eclampsia; 94 
4. Evidence for how maternal inflammation may lead to altered neurodevelopmental 95 
outcomes in pre-eclampsia exposed offspring. 96 
 97 
2. Hypertensive disorders of pregnancy: 98 
Hypertensive disorders of pregnancy (HDP) may be chronic (pre-dating pregnancy or 99 
diagnosed before 20 weeks’ gestation) or arise de novo (either pre-eclampsia or gestational 100 
hypertension). HDP are one of the most common gestational complications affecting 3-10% of 101 
all pregnancies and are made up of a collection of hypertensive conditions including pre-102 
existing hypertension (chronic hypertension), gestational hypertension, white coat hypertension 103 
and pre-eclampsia (Brown et al., 2018a).  Of these, pre-eclampsia is one of the leading causes 104 
of maternal mortality and morbidity and has recently been redefined by the International 105 
Society for the study of Hypertension in Pregnancy (ISSHP) as gestational hypertension 106 
(systolic BP > 140 and/or diastolic BP >90 mmHg) accompanied by one or more of the 107 
following new-onset conditions at or after 20 weeks’ gestation (Brown et al., 2018b):  108 
1. Proteinuria;  109 
2. Other maternal organ dysfunction, including: 110 
 Acute kidney injury (creatinine > 90umol/L; 1mg/dL)  111 
 Liver involvement (elevated transaminases e.g. ALT or AST >40 IU/L) with or 112 
without right upper quadrant or epigastric abdominal pain) 113 
 Neurological complications (examples include eclampsia, altered mental status, 114 
blindness, stroke, clonus, severe headaches, persistent visual scotomata) 115 
 Haematological complications (thrombocytopenia – platelet count below 116 
150,000/uL, DIC, hemolysis) 117 
3. Uteroplacental dysfunction (such as fetal growth restriction, abnormal umbilical artery 118 
Doppler wave form analysis, or stillbirth).  119 
Previously thought to be simply due to impaired trophoblast invasion followed by the 120 
development of the clinical manifestations of the disease, it is now appreciated that the 121 
underlying aetiology of pre-eclampsia is far more complex. Beginning with genetic 122 
susceptibility, followed by an abnormal immune adaptation to pregnancy, this in turn leads to 123 
impaired placentation and the subsequent perfusion of the intervillous space by oxygenised 124 
arterial blood resulting in excessive or deficient placental derived factors in the maternal 125 
circulation (Chaiworapongsa et al., 2014a; Chaiworapongsa et al., 2014b). The endothelial 126 
dysfunction, resulting from placental ischemia and release of placental products which occurs 127 
in pre-eclampsia appears to occur as a result of oxidative stress and is mediated by high levels 128 
of free radicals and low levels of antioxidants (Roberts and Cooper, 2001; Roberts and 129 
Gammill, 2005; Roberts and Hubel, 2004; Roberts and Lain, 2002; Roberts and Speer, 2004; 130 
Roberts et al., 1989). Vasoactive factors released include soluble fms-like tyrosine kinase-1 131 
(sFlt-1), cytokines, angiotensin II and type 1 receptor autoantibodies (Conrad and Benyo, 1997; 132 
Maynard et al., 2003; Rinehart et al., 1999; Roberts et al., 1991; Wallukat et al., 1999). These 133 
factors target the maternal vascular endothelium giving rise to the maternal syndrome of 134 
hypertension, proteinuria, organ and uteroplacental dysfunction which may be followed by 135 
acute atherosis in the spiral arteries predisposing to spiral artery thrombosis and placental 136 
infarcts (Lindheimer and Katz, 1981; Redman, 2014).  In addition, there is an increasing 137 
awareness that pre-eclampsia leads to a state of exaggerated maternal inflammation as a direct 138 
result of the underlying pathophysiology, and perhaps also indirectly by risk factors such as 139 
maternal obesity which is known to lead to chronic low-grade inflammation (Chaiworapongsa 140 
et al., 2014b; Jaaskelainen et al., 2018; Nelson et al., 2010; Segovia et al., 2014; Spradley et 141 
al., 2015). Therefore pre-eclampsia may be a common cause of maternal inflammation during 142 
pregnancy, which is a recognised risk factor for adverse neurodevelopmental outcomes 143 
(Knuesel et al., 2014). Consequently, there has been a growing interest in studying maternal 144 
inflammation and subsequently neurodevelopmental outcomes in offspring exposed to pre-145 
eclampsia.  146 
 147 
3. Maternal inflammation in pre-eclampsia: a potential role for Interleukin-6 and tumor 148 
necrosis factor (TNF)-? 149 
In uncomplicated pregnancies there is a normal systemic inflammatory response in which 150 
cytokines promote the infiltration of the spiral arteries by invading trophoblast cells (Redman 151 
et al., 1999). This is an important feature of normal placentation and occurs early in pregnancy. 152 
However this normal inflammatory response becomes exaggerated in pre-eclampsia resulting 153 
in disruptive activation of monocytes, granulocytes and the endothelium resulting in a state of 154 
maternal inflammation (Redman and Sargent, 2003). It has been proposed that there may be a 155 
genetic susceptibility to inflammation in pre-eclampsia yet many studies are conflicting (for 156 
recent review see (Thakoordeen et al., 2018). A meta-analysis of maternal polymorphisms in 157 
interleukin (IL)-6 (174G/C) (n = 396 pre-eclampsia and n = 507 normotensive) and tumor 158 
necrosis factor (TNF)- (308G/A) (n = 1888 pre-eclampsia and n = 2497 normotensive) found 159 
that these were not associated with pre-eclampsia, despite maternal IL-6 and TNF- levels 160 
being significantly higher in patients with pre-eclampsia (Xie et al., 2011). This suggests that 161 
elevations in cytokines may be as a result of the primary pathophysiology. However some 162 
subsequent studies have reported opposing findings (Sowmya et al., 2015) and this remains a 163 
topic of on-going investigation (Thakoordeen et al., 2018). However what is clear is that many 164 
clinical studies have now reported that women with pre-eclampsia have increased levels of 165 
inflammatory cytokines including IL-6, TNF-α, IL-12 and IL-16, which cause structural and 166 
functional changes in endothelial cells, promote the formation of endothelin and reduce 167 
acetylcholine induced vasodilatation (Benyo et al., 2001; Conrad and Benyo, 1997; Greer et 168 
al., 1994; Gu et al., 2008; Kupferminc et al., 1994; Lefer and Ma, 1993; Marsden and Brenner, 169 
1992; Meekins et al., 1994; Pober and Cotran, 1990; Vince et al., 1995; Visser et al., 1994). A 170 
systematic review and meta-analysis published in 2013 tested the association between pre-171 
eclampsia and maternal circulating levels of IL-6 (n = 425 pre-eclampsia and n = 363 172 
normotensive), IL-10 (n = 180 pre-eclampsia and n = 175 normotensive) and TNF-α (n = 1015 173 
pre-eclampsia and n = 925 normotensive) (Lau et al., 2013). Third trimester maternal 174 
circulating levels of IL-6, IL-10 and TNF- were significantly higher in women with pre-175 
eclampsia compared to normotensive controls (Lau et al., 2013). Subsequently a number of 176 
studies have extended and corroborated these findings. 177 
A study by Mihu et al examined maternal cytokine concentrations between 28 and 41 178 
weeks’ gestation in an uncomplicated pregnancy group (n = 78), a pre-eclampsia group (n = 179 
80), and a non-pregnant control group (n = 72) and reported elevations in IL-6 and TNF- in 180 
the pre-eclampsia group (Mihu et al., 2015). In support of this, a study by Valencia-Ortega et 181 
al also examined IL-6 levels in age-matched pregnant women with (n = 50) and without pre-182 
eclampsia (n = 50). They reported that maternal serum concentrations of IL-6 were 183 
significantly higher in late-onset pre-eclampsia, compared to early-onset pre-eclampsia or 184 
uncomplicated pregnancy (Valencia-Ortega et al., 2018). Moreover while mid-gestation 185 
circulating IL-6 levels were associated with pre-eclampsia, IL-6 was only significantly 186 
associated with term pre-eclampsia, suggesting that elevations in IL-6 may be a late stage 187 
feature of pre-eclampsia (Taylor et al., 2016b). This is consistent with a study of women with 188 
pre-eclampsia (n = 208) and normotensive controls (n = 411) which showed that first and 189 
second trimester levels of IL-6 were not associated with pre-term pre-eclampsia (Taylor et al., 190 
2016a). Interestingly given that we and others have reported that the stage of pregnancy in 191 
which offspring are exposed to maternal inflammation is a key determinant of 192 
neurodevelopmental outcomes in exposed offspring (Aguilar-Valles and Luheshi, 2011; 193 
Boksa, 2010; Fortier et al., 2007; Meyer et al., 2006; Straley et al., 2014; Straley et al., 2017), 194 
it is possible that the effects of pre-eclampsia on offspring neurodevelopmental outcomes may 195 
vary depending on the severity and clinical course of the disease. 196 
These findings are also supported by animal modelling of the pathophysiological 197 
mechanisms that underlie the development of pre-eclampsia. Specifically, the reduced uterine 198 
perfusion pressure (RUPP) rat model of placental ischemia mimics many of the clinical 199 
characteristics of pre-eclampsia. Placental ischaemia generated by reductions in uterine 200 
perfusion pressure in pregnant rats increases blood pressure, reduces glomerular filtration rate 201 
(GFR), increases sFlt-1 concentrations, elevates production of pro-inflammatory cytokines and 202 
reactive oxygen species (ROS) and leads to intrauterine growth restriction (IUGR) (Granger et 203 
al., 2006). Recent studies in the RUPP model have described an immune imbalance 204 
characterised by increased pro-inflammatory CD4+ T cells and pro-inflammatory cytokines in 205 
addition to a reduction in regulatory T cells and anti-inflammatory cytokines (Cornelius, 2018). 206 
Specifically there is substantial evidence of increased serum levels of pro-inflammatory 207 
cytokines IL-6 (Gadonski et al., 2006) and TNF-α (LaMarca et al., 2008) in response to 208 
placental ischemia in the RUPP model compared to sham controls. Initial work infusing TNF-209 
α at day 14 of gestation in pregnant rats reported a significant increase in mean arterial blood 210 
pressure and a reduction in renal iNOS production coincident with two-fold increase in plasma 211 
TNF-α levels (Alexander et al. 2002). This work was extended to examine the role of 212 
endothelin in mediating the effect of TNF-α-induced hypertension in pregnant rats (LaMarca 213 
et al. 2005). The TNF-α-induced hypertension was associated with an increase in 214 
preproendothelin expression in placenta, aorta and kidneys. Additionally, pre-treating these 215 
pregnant rats with an endothelin receptor A antagonist prior to TNF-α infusion abolished the 216 
increase in mean arterial pressure. Interestingly, chronic infusion of TNF-α had no effect on 217 
mean arterial blood pressure in virgin rats (LaMarca et al. 2005).  Furthermore, inhibition of 218 
TNF-α using the soluble receptor etanercept significantly reduced mean arterial pressure and 219 
rescued fetal growth restriction in RUPP rats (LaMarca et al. 2008). A study by Gadonski et al 220 
examined the role of IL-6 in generating pre-eclampsia-like characteristics by infusing pregnant 221 
rats with IL-6 for 5 days resulting in a 2-3 fold increase in serum IL-6 levels. As a result of the 222 
increase in circulating IL-6 levels these rats had elevated mean arterial pressure, reduced renal 223 
plasma flow and reduced glomerular filtration rates (Gadonski et al., 2006). Interestingly, these 224 
pre-eclampsia-like characteristics were not evident in virgin rats infused with IL-6 (Gadonski 225 
et al., 2006). These data indicate that elevations in maternal IL-6 may be part of the maternal 226 
inflammatory pathophysiology of pre-eclampsia. 227 
 228 
4. The epidemiological evidence for alterations in neurodevelopmental outcomes in 229 
offspring exposed to pre-eclampsia: 230 
We recently conducted a systematic review synthesising published, epidemiological evidence 231 
examining the association between HDP and neurodevelopmental disorders in the offspring 232 
(Maher et al., 2018). The primary outcomes included in the review were ASD and attention 233 
deficit hyperactivity disorder (ADHD). Secondary outcomes included behavioural outcomes 234 
such as Asperger’s Syndrome, Pervasive Developmental Disorder - Not Otherwise Specified 235 
(PDD-NOS), behavioural difficulties using standardised checklists, as well as cognitive 236 
functioning, developmental delay and intellectual disability. In total, 61 papers were included 237 
in the review: 20 for ASD (six cohort studies and 14 case-control studies), 10 for ADHD (five 238 
cohort studies and five case-control studies) and 31 secondary outcome papers (25 cohort 239 
studies and six case-control studies). 240 
Pooled results from this study showed that exposure to HDP (including pre-eclampsia, 241 
gestational hypertension and chronic hypertension) was associated with a 35% increase in the 242 
odds of ASD when compared to those unexposed to HDP (OR=1.35; 95% CI: 1.11-1.64) 243 
(Maher et al., 2018). Subgroup analysis examining pre-eclampsia alone and ASD increased the 244 
odds ratio to 1.50 (95% CI: 1.26-1.78), whereas all other HDP (which may include pre-245 
eclampsia) were associated with a non-significant increase in the odds of ASD (OR: 1.25, 95% 246 
CI: 0.90-1.73) (Maher et al., 2018) (see Table 1). However, it is important to note that the 247 
epidemiological evidence in this area is largely inconsistent. For example, some studies 248 
suggested that exposure to pre-eclampsia may be associated with a statistically significant 249 
increase in the likelihood of ASD, when compared to unexposed offspring (Buchmayer et al., 250 
2009; Curran et al., 2018; Dodds et al., 2011; Lyall et al., 2012; Mann et al., 2010; Nath et al., 251 
2012; Polo-Kantola et al., 2014; Walker et al., 2015), while others proposed a positive other 252 
HDP-ASD relationship (Curran et al., 2018; Dodds et al., 2011; Nath et al., 2012; Polo-Kantola 253 
et al., 2014). Similarly, there are studies that alluded to a positive pre-eclampsia-ASD 254 
relationship, (Bilder et al., 2009; Buchmayer et al., 2009; Burstyn et al., 2010; Hultman et al., 255 
2002; Krakowiak et al., 2012; Larsson et al., 2005; Mrozek-Budzyn et al., 2013) and others a 256 
HDP-ASD relationship (Bilder et al., 2009; Buchmayer et al., 2009; Hultman et al., 2002; 257 
Krakowiak et al., 2012) but failed to meet statistical significance. Conversely, some older 258 
studies are suggestive of a protective association between pre-eclampsia and ASD (Deykin and 259 
MacMahon, 1980; Glasson et al., 2004; Langridge et al., 2013; Lyall et al., 2012; Mason-260 
Brothers et al., 1990; Matsuishi et al., 1999), and other HDP-ASD (Lyall et al., 2012; Langridge 261 
et al., 2013), but only two of these found a statistically significant relationship (Langridge et 262 
al., 2013; Mason-Brothers et al., 1990).  263 
Given the non-significant pooled estimate seen with other HDP and ASD, it is difficult 264 
to hypothesise whether the type of HDP is an important factor in determining the impact on 265 
ASD risk in exposed offspring. The subgroup analysis by Maher et al (Maher et al., 2018) 266 
reported a highly statistically significant association between pre-eclampsia and ASD but a 267 
non-significant risk of ASD with other HDP (including pre-eclampsia). This may suggest that 268 
the association observed occurs not as a result of exposure to hypertension but as a result of 269 
exposure to a mediator of the complex syndrome of pre-eclampsia such as inflammation. More 270 
research is needed on the association between the type of HDP and ASD in order to examine 271 
whether pre-eclampsia only, or all HDP display a significant association with ASD. 272 
Although the findings show an apparent HDP-ASD relationship, results may need to be 273 
interpreted with caution as several limitations were identified among ASD studies. Firstly, 274 
misclassification bias could have resulted from a lack of validated questionnaires and maternal 275 
reporting of exposure and ASD status when determining exposure and outcome status of 276 
subjects (Curran et al., 2018; Krakowiak et al., 2012; Lyall et al., 2012; Walker et al., 2015). 277 
Secondly, confounding is of particular concern in observational studies due to the lack of 278 
randomisation process, potentially leading to spurious findings. The vast majority of studies 279 
identified in the systematic review failed to control for a combination of key variables, calling 280 
into question the validity of findings. For example, only one study controlled for a combination 281 
of key variables such as maternal age, socio-economic status, ethnic origin and maternal 282 
depression (Curran et al., 2018). Finally, several studies contained small sample sizes, evident 283 
in 5 of 20 studies which had fewer than 10 cases of ASD exposed to HDP (Bilder et al., 2009; 284 
Deykin and MacMahon, 1980; Matsuishi et al., 1999; Mrozek-Budzyn et al., 2013; Nath et al., 285 
2012). However, results of larger studies (> 10 exposed cases) that controlled for at least one 286 
potential confounder in the analysis phase of the study ranged from an OR of 1.36 to 2.36 for 287 
pre-eclampsia and 0.96 to 2.83 for other HDP (which may have included pre-eclampsia) 288 
(Maher et al., 2018).  289 
In addition, while the results of the systematic review also suggest an association 290 
between pre-eclampsia and ASD, this association may not be specific to ASD (Maher et al., 291 
2018). For example, adjusted pooled results in Maher et al also proposed that offspring exposed 292 
to HDP were 30% more likely to have ADHD compared to those unexposed. Subgroup 293 
analyses investigating a pre-eclampsia-ADHD relationship in isolation did not change this 294 
estimate, while the odds of ADHD was associated with a 70% increase in relation to other HDP 295 
(Maher et al., 2018). Moreover, while the evidence remains inconsistent among secondary 296 
outcome studies included in the review, there were some patterns of association between HDP 297 
and intellectual disability (ID) despite methodological differences between studies (Eaton et 298 
al., 2001; Griffith et al., 2011; Langridge et al., 2013; Salonen and Heinonen, 1984). For 299 
example, results from Griffith et al 2011 suggested that pre-eclampsia/eclampsia was 300 
associated with a 38% increase in the odds of ID (95% CI: 1.16, 1.64) (Griffith et al., 2011). 301 
Similarly, the relative risk for an eclampsia-‘mental retardation’ relationship classified 302 
according to ICD coding was 3.03 in Danish offspring less than 15 years old (Eaton et al., 303 
2001). Langridge et al measured ID using the American Association on Mental Retardation 304 
classification system and suggested an association between HDP and moderate ID in Western 305 
Australia (OR: 1.39, 95% CI: 1.25, 1.54) (Langridge et al., 2013). Lastly, Salonen and 306 
Heinonen  used a standardised set of tests for mental performance and suggested that HDP was 307 
associated with an increased likelihood of ‘mental retardation’ in children aged 9-10 years in 308 
Eastern Finland (RR: 6.1, 95% CI: 1.3, 28.9) (Salonen and Heinonen, 1984). 309 
Collectively, the epidemiological evidence points to an apparent relationship between 310 
pre-eclampsia exposure in particular, and ASD risk in exposed offspring. However, the 311 
specificity of the effects of pre-eclampsia on ASD risk, could in fact be associated with poor 312 
neurodevelopmental outcome in general as opposed to being specific to ASD (Bodnar et al., 313 
2018). Given the available evidence that pre-eclampsia and other HDPs may impact 314 
neurodevelopmental outcomes (Maher et al., 2018), there has been an increasing focus on 315 
identifying any neuroanatomical alterations in the brain of offspring exposed to pre-eclampsia.  316 
 317 
5. Evidence for long-term changes in the brains of offspring exposed to pre-eclampsia: 318 
An increasing body of work has now shown that the brains of women with pre-eclampsia can 319 
undergo structural and functional changes as a result of pre-eclampsia with the suggestion that 320 
this may predispose to developing neurological deficits later in life (for a comprehensive 321 
review see (Ijomone et al., 2018). However, aside from the maternal neurological changes, 322 
there is increasing interest in the long-term changes in brains of exposed offspring. In rodent 323 
models, we have recently shown that a mild prenatal hypoxia-ischemia insult which mirrors a 324 
specific aspect of the pre-eclamptic pathology just prior to delivery, did not affect brain or birth 325 
weight, but led to social behavioural deficits in exposed offspring at postnatal day 30 (Driscoll 326 
et al., 2018). The offspring also had elevations in circulating adrenocorticotropic hormone and 327 
corticosterone indicating an exaggerated stress response, coupled with elevations in IL-6 and 328 
IL-1β but not TNF-α mRNA and protein in the brain and blood samples (Driscoll et al., 2018), 329 
which have been shown in a recent systematic review and meta-analysis to be elevated in ASD 330 
(Masi et al., 2015). These cytokines may also contribute to the evolution behavioural 331 
abnormalities in the post-natal period given that postnatal administration of IL-1Ra protected 332 
against prenatal-LPS-induced changes in brain development and associated functional deficits 333 
(Girard et al., 2012). These data suggest there may be long-term changes in the brains of pre-334 
eclampsia exposed offspring, and characterising these changes has been the focus of recent 335 
investigations in human populations. 336 
A recent imaging study has examined regional brain volumes and cerebral vasculature 337 
of children aged 7 to 10 years after exposure to pre-eclampsia (Ratsep et al., 2016). Specifically 338 
children that had been exposed to pre-eclampsia (mean age = 9.79 ± 0.89 years; n = 10; 5 male, 339 
5 female) were matched based on age and sex to those born from an uncomplicated pregnancy 340 
(mean age = 9.66 ± 1.07 years; n = 10; 5 male, 5 female). This cohort then underwent magnetic 341 
resonance (MR) imaging to identify any brain structural and vascular anatomic 342 
differences. While there were no significant differences in total intracranial brain volume 343 
between the control group and children from mothers exposed to pre-eclampsia, the pre-344 
eclampsia group had significant larger regional brain volumes in five of twenty-one regions 345 
analysed that included the cerebellum, temporal lobe, left amygdala, right amygdala and the 346 
brainstem (Ratsep et al., 2016). It is important to note however that there were no significant 347 
differences in gestational age (controls = 39.47 ± 1.38 weeks vs. pre-eclampsia = 37.16 ± 3.34 348 
weeks), there was a significant difference in birth weight (controls = 3.42 ± 0.36 kg vs. pre-349 
eclampsia = 2.67 ± 0.79 kg) in this study which may have confounded these results (Ratsep et 350 
al., 2016).  351 
Interestingly, however, these alterations in regional brain volumes have also been 352 
reported in children with ASD (Ha et al., 2015; Lainhart, 2015). In particular, the increases in 353 
amygdala volume has been reported in a number of studies (Nordahl et al., 2012). In addition, 354 
a recent follow up study in this same cohort as Ratsep et al, employed diffusion tensor MR 355 
imaging (DTI) to examine myelination patterns and white matter connectivity and six brain 356 
regions of interest were identified for analysis by tractography (middle occipital gyrus, caudate 357 
nucleus and precuneus, cerebellum, superior longitudinal fasciculus, and cingulate gyrus) 358 
(Figueiro-Filho et al., 2017). They reported increased tract volumes in a number of these brain 359 
regions including the superior longitudinal fasciculus, which is strongly related to language 360 
and communication pathways (Kamali et al., 2014). Interestingly, while the molecular 361 
mechanisms that underlying these neuroanatomical changes are unknown, a recent study have 362 
shown that exposure of fetal cortical neurons to serum of women with established pre-363 
eclampsia lead to increases in axonal growth and branching (Curran et al., 2018). This suggests 364 
that pre-eclampsia exposure may alter neurodevelopmental trajectories, but to our knowledge 365 
this causative basis of altered brain volumes in offspring exposed to pre-eclampsia are currently 366 
unknown and in addition these studies require confirmation in larger patient cohorts.   367 
 368 
6. How might maternal inflammation in pre-eclampsia alter neurodevelopmental 369 
outcome?  370 
Given the epidemiological evidence for an association between pre-eclampsia and 371 
neurodevelopmental outcome, then a key question is what are the mechanisms that mediate 372 
this association? Given that maternal inflammation is a core feature of the maternal 373 
pathophysiology of pre-eclampsia (Lau et al., 2013) and systematic evidence has reported 374 
maternal inflammation as a risk factor for ASD (Jiang et al., 2016), it is possible that pre-375 
eclampsia-induced maternal inflammation is a determinant of fetal neurodevelopmental 376 
outcome.  377 
Arguably IL-6 is one of the best characterised mediator of the impacts of maternal 378 
inflammation on fetal neurodevelopmental outcome. Animal models of maternal inflammation 379 
have shown that maternal administration of the viral mimetic, poly(I:C), lead to elevations in 380 
maternal and fetal IL-6 levels, and alter neurobehavioural outcomes in the offspring (Meyer et 381 
al., 2006). Blocking IL-6 signalling through maternal co-administration of anti-IL-6 antibodies 382 
with poly(I:C), prevented the poly(I:C)-induced social deficits and transcriptional changes in 383 
the brains of exposed offspring (Smith et al., 2007).  Interestingly there is also increased IL-6 384 
expression and signalling in the placenta in the poly(I:C) model suggesting that conditions that 385 
increase maternal-placental IL-6 signalling may lead to detrimental effects in the fetal brain 386 
(Hsiao and Patterson, 2011). This has recently been addressed in an elegant study by (Wu et 387 
al., 2017) who addressed the role of maternal IL-6. The authors crossed il-6+/+ males with il-6-388 
/- females (resulting in a pregnant dam who cannot mount an IL-6 response), and in parallel 389 
crossed il-6-/- males with il-6+/+ females (resulting in a pregnant dam who can mount an IL-6 390 
response). Poly(I:C) administration to these pregnant dams led to increases in fetal brain IL-6 391 
levels only in offspring from il-6+/+ females (Wu et al., 2017). Moreover, conditional deletion 392 
of the IL-6 receptor in the placental trophoblast prevented the maternal poly(I:C)-induced fetal 393 
brain inflammatory response, neuroanatomical changes and anti-social and repetitive/anxiety-394 
like behaviour in exposed offspring (Wu et al., 2017).  395 
While the majority of these studies have been carried out in rodent models, a recent 396 
study in humans reported the association between maternal IL-6 in pregnancy and the structural 397 
connectivity of frontolimbic circuitry, which is critical for socioemotional and cognitive 398 
development, in thirty infants (Rasmussen et al., 2018). Specifically, diffusion tensor imaging 399 
revealed that maternal IL-6 levels averaged across pregnancy were inversely associated with 400 
fractional anisotropy (a measure of brain connectivity) and offspring cognition at 12 months of 401 
age (Rasmussen et al., 2018). Other studies have also show that third trimester maternal IL-6 402 
levels, are associated with neonatal functional connectivity and with both fetal heart rate 403 
variability and toddler cognitive development (Spann et al., 2018). This is in agreement with 404 
the report that higher average maternal IL-6 was prospectively associated with larger right 405 
amygdala volume and selected stronger bilateral amygdala connectivity (Graham et al., 2018). 406 
Interestingly, larger newborn right amygdala volume and stronger left amygdala connectivity 407 
mediated the association between higher maternal interleukin-6 concentrations and lower 408 
impulse control at 24 months of age (Graham et al., 2018).  Moreover, mothers of children with 409 
ASD with intellectual disability had significantly elevated mid-gestational levels IL-6 (Jones 410 
et al., 2016). However while these correlations do not prove causation, recent work has shown 411 
that maternal depressive symptoms are associated with higher maternal inflammation, 412 
including IL-6, which mediates the effect on maternal report of infant negative affect 413 
(Gustafsson et al., 2018). This study provides proof-of-principle that pre-eclampsia-induced 414 
elevations in maternal IL-6 may act as a mediator of the pre-eclampsia-ASD association.  415 
Collectively these data support the premise that fetal exposure to pre-eclampsia-induced 416 
alterations in maternal IL-6 and maternal-placental IL-6 signaling may increase the risk of 417 
adverse neurodevelopmental outcomes, and perhaps even increase the risk of 418 
neurodevelopmental disorders in genetically predisposed offspring. 419 
 420 
7. Conclusions and future perspectives: 421 
Future epidemiological research examining the association between pre-eclampsia and ASD in 422 
particular and neurodevelopmental disorders in general, should address the limitations and gaps 423 
in the current literature we have recently discussed (Maher et al., 2018). In particular, large 424 
population-based cohort studies with valid methods to identify women with HDP and children 425 
with ASD are needed. It is important that such studies be able to adjust for key potential 426 
confounders such as maternal and paternal age, maternal body mass index, socio-economic 427 
status factors, behavioural factors, family history of mental disorders, ethnic origin and 428 
maternal morbidity such as diabetes. In addition, such studies should attempt to assess whether 429 
observed associations between HDP and ASD is HDP type specific, whether the association is 430 
specific to ASD, or ASD and other neurodevelopmental and psychiatric disorders. Whether 431 
other pregnancy complications and early life events have effect modification or mediation role 432 
in the HDP-ASD association is worth investigating as such analyses may improve our 433 
understanding of the association and the potential mechanisms. Moreover an important gap in 434 
the literature is the potential impact of antihypertensive medications on any observed 435 
association. In other words, is the observed association between pre-eclampsia and ASD related 436 
to the HDP or pharmacological treatments used during pregnancy? This is an important 437 
question for future research. 438 
 In future work it will also be important to examine neuroanatomical and 439 
neurobehavioural outcomes across the life span using multiple pre-clinical models of pre-440 
eclampsia, and in clinical cohorts. While the longitudinal nature of these studies are challenging 441 
in humans, imaging and developmental assessments of adequately powered cohorts of 442 
offspring exposed to pre-eclampsia and appropriate matched controls will be important given 443 
recent studies showing changes in the brains of pre-eclampsia-exposed offspring (Figueiro-444 
Filho et al., 2017; Ratsep et al., 2016). Combining this with animal modelling will allow the 445 
role of maternal inflammation and in particular IL-6 as mediator of the association to be 446 
determined, using elegant approaches reported by Wu et al (Wu et al., 2017). It will also be 447 
important to not limit studies of potential mediators to IL-6 and explore a range of other 448 
potential inflammatory mediators including but not limited to TNF- and IL-17 (Choi et al., 449 
2016; Jones et al., 2016). Moreover, given a recent study showing that most significant genetic 450 
variants associated with schizophrenia converge on a developmental trajectory sensitive to 451 
events that affect the placental response to in utero stressors, including pre-eclampsia (Ursini 452 
et al., 2018), understanding the placental response in pre-eclampsia and how this may predict 453 
or be associated with neurodevelopmental outcomes in pre-eclampsia-exposed offspring 454 
(O'Keeffe and Kenny, 2014), will be important questions for future research.   455 
 456 
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Figures and Figure Legend 786 
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 788 
Figure 1. Schema showing an overview of how pre-eclampsia may impact 789 
neurodevelopmental outcomes in exposed offspring.  While physiological levels of maternal 790 
inflammation plays a role in an uncomplicated pregnancy, the decrease in placental perfusion 791 
in pre-eclampsia leads to the increased production of pro-inflammatory cytokines including IL-792 
6 and TNF-. These cytokines may disrupt placenta signalling and/or cross to the fetal 793 
circulation to alter fetal neurodevelopmental trajectories, which may increase the risk of sub-794 
optimal neurodevelopmental outcomes in offspring exposed to pre-eclampsia. 795 
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Table 1:  Summary of studies examining pre-eclampsia and ASD 
*Adjusted result was statistically significant. 
95% confidence interval (95% CI); Pre-eclampsia (PE); Autism Diagnostic Observation Schedule (ADOS); Autism Diagnostic Interview, Revised (ADI-R); Alberta Perinatal Health Program (APHP); 
Department of Disabilities and Special Needs, South Carolina (DDSN); Medical Birth Register (MBR); Psychiatric Central Register (PCR); Diagnostic and Statistical Manual of Mental Disorders 
(DSM); not reported (NR); Diagnostic and Statistical Manual of Mental Disorders–3rd Edition Revised (DSM-III-R
Author Design N Prenatal Stressor Outcomes Results cOR/RR (95% CI) aOR/RR (95% CI) 
Walker et al., 
2015 
Case-control 867 PE from medical records or 
maternal self-reporting in 
telephone interview 
ADOS 
ADI-R 
↑ odds ASD* 2.58 (1.31, 5.11) 2.36 (1.18, 4.72) 
Mrozek-
Budzyn., 2013 
Case-control 288 PE from medical records or 
self-reporting 
ICD-10 ↑ odds ASD 2.05 (0.58, 7.28) 
 
- 
Lyall et al., 2012 Cohort 66445 Toxemia self-reported in 
questionnaire 
Maternal-reported ↑ odds ASD* 1.24 (0.99, 1.55) 1.36 (1.04, 1.78) 
Burtsyn et al., 
2010 
Cohort 216342 PE from APHP delivery 
records 
ICD-9 ↑ odds ASD 1.91 (1.30, 2.81) 1.49 (1.00, 2.22) 
Mann et al., 
2010 
Cohort 87677 PE/eclampsia from billing 
records for Medicaid-eligible 
women (ICD-9) 
ICD-9  from Medicaid 
billing records or DDSN 
↑ odds ASD* 1.85 (1.38, 2.48) 1.69 (1.26, 2.27) 
Buchmayer et 
al., 2009 
Case-control 7296 PE from MBR (ICD-9, ICD-
10) 
ICD-9,  ICD-10 ↑ odds ASD* 1.41 (0.98, 2.03) 1.64 (1.08, 2.49) 
Larsson et al., 
2005 
Case-control 18148 PE from MBR ICD-8 and ICD-10 from 
PCR 
↑ odds ASD 1.54 (0.83, 2.86) - 
Glasson et al., 
2004 
Case-control 1627 PE (ICD-9) DSM ↓ odds ASD 0.90 (0.50, 1.62) - 
Eaton et al., 
2001 
Case-control 103021 Eclampsia from MBR ICD from PCR ↓ odds ASD 0.82 (NR) - 
Matsuishi et al., 
1999 
Case-control 232 Toxemia DSM-III-R ↓ odds ASD 0.82 (0.18, 3.79) - 
Mason Brothers 
et al., 1990 
Case-control 285 Toxemia from medical 
records 
DSM-III ↓ odds ASD 0.36 (0.16, 0.83) - 
Deykin et al., 
1980 
Case-control 364 Toxemia from medical 
records and interview data 
≥1 symptoms of impaired 
relatedness to the 
environment, 
stereopathy and 
impaired language 
development 
↓ odds ASD 0.83 (0.25, 2.70) 0.90 (0.50, 1.62) 
 
